Government Affairs
Refine search
Biotechnology
A new national framework designed to strengthen the delivery of advanced therapy clinical trials across the UK has been launched by the Advanced Therapy Treatment Centre (ATTC) network, as the country seeks to reinforce its position in the fast-growing cell and gene therapy sector. 20 May 2026
Pharmaceutical
Northern Ireland’s life sciences industry is set to benefit from closer collaboration with the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), it was announced Wednesday. 14 May 2026
Pharmaceutical
India has once again been placed on the Priority Watch List in the 2026 Special 301 Report released by the Office of the United States Trade Representative (USTR). 13 May 2026
Pharmaceutical
The Wall Street Journal Editorial Board is once again raising concerns about the USA’s federal 340B drug pricing program – this time questioning whether the program is benefiting patients at all. 12 May 2026
Pharmaceutical
For the first time, Swedish pharma trade group Lif launched its own program track at Vitalis. Together with the Swedish Medical Products Agency, SweTrial and Swedish Medtech, the focus was on how Sweden can strengthen its position as an attractive clinical trial country. 11 May 2026
Biosimilars
Industry group Medicines for Europe has urged policymakers to strengthen support for biosimilar medicines, arguing that wider uptake could improve patient access to biologic therapies while reinforcing Europe’s pharmaceutical resilience. 7 May 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027. 7 May 2026
Pharmaceutical
As Europe strives to compete globally in life sciences, predictable and robust IP incentives will determine whether tomorrow’s breakthroughs are developed here or elsewhere, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). 27 April 2026
Pharmaceutical
India’s Central Drugs Standard Control Organization (CDSCO) and Brazil’s National Health Surveillance Agency (ANVISA), have established a framework to align regulatory practices. 27 April 2026
Pharmaceutical
Among significant news last week, Denmark’s Novo Nordisk presented positive results for its sickle cell disease candidate etavopivat. Eli Lilly revealed an up to $7 billion deal to acquire Kelonia Therapeutics and its gene therapy KLN-1010. The US Centers for Medicaid and Medicare Services (CMS) has extended the GLP-1 Bridge program for obesity medicines as insurers hold back. US biopharma Grace Therapeutics suffered a setback as the US Food and Drug Administration (FDA) issued a complete response letter (CRL) on the company’s new drug application (NDA) for GTx-104, which is being developed for aneurysmal subarachnoid hemorrhage (aSAH). 26 April 2026
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim’s Indian subsidiary and India’s National Institute of Pharmaceutical Education and Research (NIPER) have signed a five year memorandum of understanding (MoU) to advance pharmaceutical research, education, and innovation in eastern India. 25 April 2026
Biotechnology
Over the decades, Germany’s Bayer has played as big a part as any company in the discovery and development of innovative medicines to treat patients around the world. 24 April 2026
Pharmaceutical
The US government is set to bear the financial burden of covering blockbuster obesity medicines for Medicare beneficiaries, after private insurers balked at participating in a planned long-term payment model. 22 April 2026
Pharmaceutical
As US states debate new proposals to regulate prescription drug prices - such as prescription drug boards or referencing federal or foreign pricing - it’s critical to examine the real-world consequences of government-set prices. 22 April 2026
Pharmaceutical
Russia plans to increase public procurements of anti-cancer drugs that will be part of a new national project, which aims to ensure two-thirds of cancer patients survive five years or more after diagnosis with cancer by 2030, reports The Pharma Letter’s local correspondent. 20 April 2026
Pharmaceutical
Swiss industry group Interpharma has called for the country to maintain and expand its bilateral framework with the European Union, warning that political proposals affecting migration could disrupt the pharmaceutical sector. 20 April 2026
Pharmaceutical
US President Donald Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC) after a long search for a replacement for Susan Monarez, who was sacked in August last year. 17 April 2026
Pharmaceutical
US anti-virals specialist Gilead Sciences announced that the US State Department, the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir (marketed under the tradename Yeztugo), to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. 15 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Pharmaceutical
A new national project will develop a common information structure for clinical trials in Sweden. 13 April 2026
Pharmaceutical
If the UK is to become Europe’s leading life sciences economy by 2030, it must sharpen its global appeal and do more to attract and keep world-class talent. 30 October 2025
Pharmaceutical
Kim Assender, the Association of the British Pharmaceutical Industries’ (ABPI) director of commercial policy and analysis, explores the question: 'What is the “right” level of medicines spending to deliver optimal patient outcomes while sustaining our health system and fostering economic growth?' Drawing on a new report from IQVIA Global Market Insights, ‘Drug Expenditure Dynamics 2000–2022’. 29 October 2025
Pharmaceutical
Henrik Vestergaard, acting chief executive of Lif, the Danish Pharmaceutical Industry Association, has taken aim at the USA’s most-favored-nation (MFN) drug pricing policy that would tie US prices of prescription drugs to the lowest prices paid in other developed countries. 27 October 2025
Generics
The Association for Accessible Medicines (AAM) has filed for a federal injunction to prevent Connecticut from enforcing a new price-control law that it says threatens patient access to low-cost drugs and violates the US Constitution. The request was submitted October 23 in the US District Court for the District of Connecticut. 24 October 2025
Generics
The Russian government plans to double the volume of localized active pharmaceutical ingredients (APIs) within the next five years, that will ensure Russia’s state security in the field of pharmaceutics. 22 October 2025
Pharmaceutical
US President Donald Trump has said the USA aims to apply favored-nation pricing to popular weight-loss medicines, pointing to a possible drop from $1,300 to about $150 per month. Markets reacted Friday, with Novo Nordisk falling more than 6% and Eli Lilly down over 3%. 20 October 2025
Pharmaceutical
Sweden’s life science sector, now worth an estimated 474 billion Swedish kroner ($50 billion) in annual sales, has become one of the country’s most dynamic growth engines. But according to Lif expert Frida Lundmark, the nation’s advanced research infrastructure must be more closely connected to healthcare delivery if Sweden is to position itself as a global leader in life sciences. 20 October 2025
Pharmaceutical
The European Parliament’s rapporteur has recently presented draft reforms to the proposed EU Critical Medicines Act, emphasizing stronger investment in domestic manufacturing while expanding stockpiling measures to secure medicine supply across member states. 17 October 2025
Pharmaceutical
German pharma group Merck KGaA has become the third company to strike a cost-cutting agreement with the Trump administration, joining Pfizer and AstraZeneca in pledging steep price reductions in exchange for relief from planned US tariffs on drug imports. 17 October 2025
Pharmaceutical
The USA’s 340B hospital markup program is costing taxpayers an estimated $13.4 billion a year in lost Medicare rebates, according to a new report from Berkeley Research Group (BRG). 16 October 2025
Pharmaceutical
Iceland’s budget for licensed medicines should takes into account the rapid development of new medicines, the increasing number of people with serious diseases and their access to the best possible treatment. 13 October 2025
Pharmaceutical
The Gulf's leaders have spent years promising to diversify their economies beyond oil. Pharmaceuticals and biotechnology now stand near the top of that agenda, positioned as strategic industries that promise health security, jobs and prestige. 13 October 2025
Pharmaceutical
The Irish Pharmaceutical Healthcare Association (IPHA), the representative body for the research-based biopharmaceutical industry in Ireland, welcomes the allocation of 30 million euros ($34.7 million) for new, life-enhancing medicines in Budget 2026. 13 October 2025
Pharmaceutical
Danish pharma major Novo Nordisk is considering its options after a US federal appeals court threw out its legal challenge to the Inflation Reduction Act (IRA) drug price negotiation program. 9 October 2025
Pharmaceutical
The UK government is weighing changes to how the NHS assesses the cost-effectiveness of medicines, in a move that could raise drug prices. Reports suggest ministers are considering increasing the threshold used by the National Institute for Health and Care Excellence (NICE) by 25%. 9 October 2025
Generics
In a strategic move to rebalance trade with India, Russian President Vladimir Putin has directed his government to ramp up imports of Indian pharmaceuticals and agricultural products. 6 October 2025
Generics
In what is being termed a major boost to India’s pharmaceutical export industry, China has announced the immediate removal of its 30% import duty on Indian pharmaceutical products. 6 October 2025
Biotechnology
San Diego, USA-based biotech Cidara Therapeutics yesterday revealed it has received an award valued up to $339 million from the Biomedical Advanced Research and Development Authority (BARDA). 3 October 2025
Pharmaceutical
The US Food and Drug Administration (FDA) will not be able to deal with new drug applications amid the federal government shutdown. 2 October 2025
Pharmaceutical
New York Attorney General Letitia James announced a settlement with the US unit of UK-based pharma company Indivior, stopping the company’s misleading promotion of its opioid overdose drug, Opvee (nalmefene). 2 October 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze